Melkart Duo (Metformin Hydrochloride, Vildagliptin)

Metformin hydrochloride lowers blood glucose primarily by inhibiting hepatic gluconeogenesis, reducing the amount of glucose released by the liver. It also enhances peripheral insulin sensitivity, facilitating greater glucose uptake by muscle and adipose tissue, and modestly decreases intestinal absorption of glucose, contributing to overall glycaemic reduction.

Vildagliptin is a selective dipeptidyl peptidase‑4 (DPP‑4) inhibitor. By blocking DPP‑4, it prevents the rapid degradation of endogenous incretin hormones (GLP‑1 and GIP), which in turn increases insulin secretion and suppresses glucagon release in a glucose‑dependent manner, improving post‑prandial glucose control.

The specific dose of Melkart Duo is individualized by the prescribing clinician based on factors such as the patient’s current glycaemic status, renal function, concomitant medications, and response to therapy. The prescriber determines the appropriate tablet strength and dosing frequency, and adjustments are made during follow‑up visits.

Safety of Melkart Duo in pregnancy and lactation has not been fully established. Clinicians should weigh potential benefits against possible risks, considering alternative treatments when possible. If therapy is deemed necessary, it should be used under close medical supervision, and breastfeeding mothers should be monitored for any adverse effects in the infant.

To order Melkart Duo, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any required temperature control) and assistance with import documentation.

Compared with sulfonylureas, Melkart Duo offers glucose‑dependent insulin secretion, reducing the risk of hypoglycaemia. Unlike metformin monotherapy, the addition of vildagliptin provides further post‑prandial glucose reduction. Relative to other DPP‑4 inhibitor combinations, the fixed‑dose format simplifies dosing and may improve adherence, though efficacy and safety profiles remain comparable across agents within the same class.

Melkart Duo tablets should be stored at ambient temperature, preferably below 25 °C, in their original blister or container to protect from moisture and light. Do not expose the product to excessive heat, humidity, or direct sunlight, and keep it out of reach of children. No refrigeration is required for this oral formulation.

Melkart Duo is taken orally, usually with a meal to minimise gastrointestinal discomfort. The tablet should be swallowed whole with a full glass of water; it should not be crushed, chewed, or split unless specifically instructed by a healthcare professional. Adherence to the prescribed dosing schedule is important for optimal glycaemic control.

The most serious risks associated with Melkart Duo include lactic acidosis, a rare but potentially fatal condition linked to metformin, and severe hypoglycaemia, especially when combined with insulin or sulfonylureas. Acute pancreatitis has also been reported with DPP‑4 inhibitors. Patients should be educated to recognize early symptoms and seek immediate medical attention if they occur.